Efficacy of Green Tea Buccal Tablets in Oral Lichen Planus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03415165 |
Recruitment Status : Unknown
Verified January 2018 by Esraa Magdy, Cairo University.
Recruitment status was: Recruiting
First Posted : January 30, 2018
Last Update Posted : February 13, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Oral Lichen Planus | Drug: green tea buccal tablet Drug: Corticosteroids Topical | Early Phase 1 |
- Each patient was informed about the detailed procedure, and educated about benefits of the treatment, the known side effects and follow-up appointments needed. After that, each subject participating in the study signed an informed written consent form.
- Subjects were given freedom to leave the study at any time when they need to. Group A (Experimental group) 200 mg green tea
Where patients in this group will receive a buccal tablet containing 200 mg of green tea extract which adheres to the buccal mucosa slowly releasing the polyphenoles along around 8 hours 2 times aday for four weeks.
Preparation of buccal tablets : Mucoahesive buccal tablets is prepared by a direct compression procedure. Various batches are prepared by varying the chitosan:drug ratio to identify the most effective formulation. The mucoadhesive drug/polymer mixture is prepared by homogeneous mixing of the drug with chitosan , secondary polymer, and D-mannitol, in a glass mortar for 15 min. Then, Mg stearate will be added and mixed for 5 min .The mixture is compressed using a tablet machine (Type EK: O.Erweka apparatus, Frankfurt, Germany) using flat-tip punches and dies with 8-mm-diameter. Each tablet weighed 212 mg with a thickness of 3.1 mm.( Darwish and Elmeshad,2009)
Group B (Experimental group) 300 mg green tea
Where patients in this group will receive a buccal tablet containing 300 mg of green tea extract which adheres to the buccal mucosa slowly releasing the polyphenoles along around 8 hours 2 times aday for four weeks.
Group C (Control group) corticosteroid group:
Where patients are treated with topical corticosteroids 1 mg/g Triamcinolone acetonide (Kenacort-A orabase 20 G Pomad: Deva dermatological product,Turkey) applied topically 4 times a day i.e. following each meal and at bed time for four weeks .
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of 200mg and 300mg Concentrates of Green Tea Polyphenols Using Buccal Tablets Versus Topical Application of Corticosteroids in Treatment of Patients With Symptomic Oral Lichen Planus Randomized Clinical Trial |
Actual Study Start Date : | January 3, 2018 |
Estimated Primary Completion Date : | January 30, 2019 |
Estimated Study Completion Date : | January 30, 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: green tea buccal tablet
buccal tablet 3 times aday
|
Drug: green tea buccal tablet
buccal tablet for 8 hrs 3 times aday
Other Name: catechines |
Sham Comparator: corticosteroids topical
topical steroids 3 times aday
|
Drug: Corticosteroids Topical
kenacort in orabase 4 times aday
Other Name: local corticosteroids |
- size of the lesion [ Time Frame: 12 weeks ]the shape and the measurement of its size
- visual analogue score [ Time Frame: 12 weeks ]pain score from 0 to 10

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 17 Years to 80 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Symptomatic lesions.
- OLP lesions with the diagnosis confirmed both clinically and histopathologically.
- Clinical score higher than 3.
- Disease duration of more than 2 months.
- Absence of dysplasia in histological section
Exclusion Criteria:
- Presence of any visible oral lesion other than OLP.
- Pregnant or breast-feeding women,
- Immuno-deficiency diseases.
- Current malignancy or malignancy in history.
- Concomitant treatment potentially effective on OLP within the previous 2 months such as antimalarial agents, retinoids, corticosteroids or immunosuppressive drugs.
- Severe or recurrent infections.
- Lichenoid reaction.
- Patients presents with skin lesions which may require systemic corticosteroid therapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03415165
Contact: EMagdy baligh, master | 01003329610 | esraa_magdy@dentistry.cu.edu.eg | |
Contact: esraa baligh, master | 01003329610 | esraa_magdy@dentistry.cu.edu.eg |
Egypt | |
Cairo University | Recruiting |
Cairo, Egypt, 00202 | |
Contact: cairo university ethics@dentistry.cu.edu.eg | |
Contact: cairo university |
Study Chair: | cairo university | cu |
Responsible Party: | Esraa Magdy, princible investigator EMagdy, Cairo University |
ClinicalTrials.gov Identifier: | NCT03415165 |
Other Study ID Numbers: |
161187 |
First Posted: | January 30, 2018 Key Record Dates |
Last Update Posted: | February 13, 2018 |
Last Verified: | January 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Lichen Planus, Oral Lichen Planus Lichenoid Eruptions Skin Diseases, Papulosquamous |
Skin Diseases Mouth Diseases Stomatognathic Diseases |